Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Policies & Guidelines
Filter by Topic
Best Practices
Clinical Guidelines
End-of-Life Care
Health Policy
NCCN 2015 Updates
NCCN Guidelines
Pathways
Patient Advocacy
Patient Navigation
Quality Care
Survivorship
Survivorship Care
Implications of Healthcare Reform for Oncologists and Cancer Care
Cancer Care
,
Health Policy
,
Policies & Guidelines
,
Personalized Medicine
July 2011, Vol 2, No 4
The healthcare reform legislation involves many potential issues that can affect oncology, for example, how minimum benefits are defined. First, there are required minimum benefits that all health plans and other insurers have to meet, and we have to make sure that cancer care is included.
Read Article
Patient Navigation and Patient Assistance Programs in Oncology
By
Wayne Kuznar
Patient Navigation
,
Policies & Guidelines
July 2011, Vol 2, No 4
The medically under - served population needs easier access to healthcare and tools that provide a seamless transition between all phases of the treatment process, from screening through therapy and survivorship.
Read Article
Evidence-Based Practice Should Drive Patient Care
NCCN Guidelines
,
Policies & Guidelines
July 2011, Vol 2, No 4
Read Article
NCCN Guidelines Inform Decisions Across the Continuum of Cancer Care
By
Wayne Kuznar
NCCN Guidelines
,
Policies & Guidelines
July 2011, Vol 2, No 4
Philadelphia, PA—The National Com - prehensive Cancer Network (NCCN) is an alliance of academic cancer centers in the United States that seeks to optimize decision-making and policies for improving the delivery of appropriate and effective cancer care.
Read Article
Accountable Care Organizations: Implications for Oncologists
By
Rhonda Greenapple, MSPH, Reimbursement Intelligence
Health Policy
,
Policies & Guidelines
June 2011, Vol 2, No 3
The journey for healthcare costsavings is a never-ending process. One of the newest healthcare delivery models, which is mandated for Medicare beneficiaries in the healthcare reform law, is the accountable care organization (ACO).
Read Article
ASCO Calls for Open Discussions and Individualized Care for Patients with Advanced Cancer
Health Policy
,
Policies & Guidelines
June 2011, Vol 2, No 3
Frank discussions with patients about their advanced cancer are challenging for physicians and their patients; however, avoiding such interactions is not a viable option, according to the American Society of Clinical Oncology (ASCO).
Read Article
Cancer Drug Use and Costs Sharply Rising
Health Policy
,
Policies & Guidelines
June 2011, Vol 2, No 3
There is no end in sight to the rising cost of fighting cancer, according to Medco’s 2011
Drug Trend Report
(www.drugtrendreport.com/2011-report), which forecasted the cost of cancer drugs will grow 34% to 42% over the next 3 years.
Read Article
Humana’s Real-World Data Confirm Cost-Savings with the 21-Gene Recurrence Score Assay
Health Policy
,
Policies & Guidelines
June 2011, Vol 2, No 3
A new analysis of the Humana database shows that the 21-gene recurrence score (RS) molecular assay (OncotypeDX; Genomic Health) leads to targeted management of early-stage breast cancer and reduces payer’s costs (Hornberger J, et al.
J Oncol Pract
. 2011;7[3s]:e38s-e45s).
Read Article
ODAC Supports Tightening Up Accelerated Approvals for New Cancer Drugs
By
Daniel Denvir
Health Policy
,
Policies & Guidelines
April 2011, Vol 2, No 2
Read Article
CMS’s Coverage Decision on Provenge: Implications for Payers
By
Dalia Buffery, MA, ABD
Health Policy
,
Policies & Guidelines
April 2011, Vol 2, No 2
On March 30, 2011, the Centers for Medicare & Medicaid Services (CMS) announced its highly anticipated proposed national coverage decision concerning the prostate cancer immunotherapy sipuleucel-T (Provenge; Dendreon).
Read Article
Page 10 of 11
2
3
4
5
6
7
8
9
10
11
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma